Cancer cells of growing ribociclib-resistant tumors used a diverse set of M2-like differentiation stimulating communication pathways as shown by a range of markers: CSF1, CLCF1, several FGFs (1/2/7/17/18/23), the TGF family member GDF9, interleukin 5/11/12, MADCAM1 and PLAU (Fig. 4D, left panel) (Supplementary Data 21–22). Here, PLAU is linked to cancer.